Meeting
2023 ASCO Annual Meeting
Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
Authors
Davendra Sohal
University of Cincinnati, Cincinnati, OH
Davendra Sohal , Khaled Fahmy Abouelezz , Katie Moreland , Ralph Quillin , Kristina Lemon , Adam Rojan , Olugbenga Olanrele Olowokure , Ali Kord , Shimul Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT05027425
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4188)
DOI
10.1200/JCO.2023.41.16_suppl.TPS4188
Abstract #
TPS4188
Poster Bd #
500b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
First Author: Davendra Sohal
Poster
2024 ASCO Annual Meeting
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).
First Author: Ho Yeong Lim
Poster
2017 ASCO Annual Meeting
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
First Author: Robin Kate Kelley